Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Marimed (MRMD) Accumulated Depreciation & Amortization (2016 - 2025)

Marimed (MRMD) has disclosed Accumulated Depreciation & Amortization for 10 consecutive years, with $25.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization changed N/A to $25.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $25.5 million, a N/A change, with the full-year FY2024 number at $21.6 million, up 45.11% from a year prior.
  • Accumulated Depreciation & Amortization was $25.5 million for Q3 2025 at Marimed, up from $23.7 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $25.5 million in Q3 2025 to a low of $462000.0 in Q1 2021.
  • A 5-year average of $13.2 million and a median of $10.2 million in 2022 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: decreased 4.55% in 2021, then soared 1553.03% in 2022.
  • Marimed's Accumulated Depreciation & Amortization stood at $7.0 million in 2021, then surged by 47.02% to $10.2 million in 2022, then soared by 45.89% to $14.9 million in 2023, then surged by 45.11% to $21.6 million in 2024, then rose by 17.75% to $25.5 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Accumulated Depreciation & Amortization are $25.5 million (Q3 2025), $23.7 million (Q2 2025), and $22.0 million (Q1 2025).